MORE posts
Dr. Jodi Green, Chief Scientific Officer, Inflexxion an IBH Company, was the senior author for an online research article with www.frontiersin.org that casts a new light on nonmedical use of prescription stimulants by colleges students, particularly via injection and snorting. The study also identified pathways to initiation of nonmedical use of prescription stimulants to inform public […]
Dr. Jodi Green, Chief Scientific Officer, Inflexxion and IBH Company, co-authored a research study. The following is an excerpt from www.frontiersin.org. Objective: Prescription stimulant non-medical use (NMU) is a national predicament. While the risks of prescription stimulant NMU have been considered, less is known about non-oral use. To focus on this gap, a sample of […]
Based on a recent study, our team has published an article in Pain Medicine, “Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index–Multimedia Version (ASI-MV).” For more information about this study, please see the abstract below. To obtain the full article, click here. Abstract Objective The […]
Based on a recent study, our team has published an article in the “PAINWeek Journal” titled, “Disability Claimants and the Implementation of a Web-based Pain Assessment/Pain Management Program.” For more information about this study, please see the abstract below. To obtain the full article, click here. Abstract One of the most frustrating aspects of a clinician’s work is getting […]
Based on a recent study, our team has published an article in the “Journal of Opioid Management” titled, “Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.” For more information about this study, please see the abstract below. To obtain the full article, click here. Abstract Objective: To examine abuse […]
Taryn Dailey-Govoni, Jared Beaumont, Theresa Cassidy Inflexxion, Inc., Waltham, MA, USA Presented at PAINWeek 2017 Read our poster for “Profiling non-medical use of tapentadol products among recreational drug abusers” here Abstract Purpose Prescription opioid misuse and abuse is a public health epidemic in the United States (ONDCP 2015) and a growing source of morbidity, mortality, […]
Click here to read our latest article, The Power of an Electronic Clinical Assessment for Pain and Opioid Misuse Risk: Leveraging SOAPP & COMM in a Digital Era
Inflexxion, Inc. announced today that Allscripts has certified PainCAS™ as part of the Allscripts Developer Program. PainCAS enables Allscripts ambulatory EHR users to assess pain, functioning, and risk of problematic opioid-related behaviors in patients with chronic pain. Developed in part with support from the National Institutes of Health (NIH), grants (Grant No. R44DA026359, PI S.F. Butler and Grant No. R44DA015617, PI S.F. Butler), PainCAS is a scientifically validated web-based, patient self-report clinical tool for assessing pain and opioid misuse risk in patients with chronic pain.
Jared Beaumont, M.P.H.1, Theresa Cassidy, M.P.H.1, Taryn Dailey Govoni, M.P.H.1 Presented at International Conference on Opioids 2017 See our poster for “Abuse and route of administration prevalence for tapentadol products within the NAVIPPRO® ASI-MV® surveillance system” here Abstract Post-market surveillance data indicate low abuse levels of tapentadol products, but research regarding the route of administration […]
How an electronic assessment tool can assist in meeting Tennessee Licensing for Office-Based Opiate Treatment (OBOT) Over the last few years, we have seen many states taking the initiative and implementing new rules and regulations as a result of the opioid epidemic that is sweeping our nation. On January 12, a new rule went into […]
Kimberlee J. Trudeau, Joanna Burtner, Kruti Joshi, Albert Villapiano, Megan Jones, & Stephen F. Butler Presented at ARM 2016 See our poster for “A Cross-Sectional Analysis of Economic, Medical, and Legal Outcomes of Adults in Substance Abuse Treatment centers with Possible or Probable Schizophrenia” here Research Objective: In the fragmented US healthcare system, patients seeking substance abuse […]
Earlier this year, Inflexxion and KemPharm Pharmaceuticals presented a poster at the International Conference on Opioids based on a recent study of non-medical use of prescription opioids. According to SAMSHA, Non-medical use of prescription opioids continues to increase. However, little is known about the potential impact commonly prescribed opioids, such as hydrocodone combination products (HCPs), have […]